Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kraken's release is only legal in California.
NEWS -- Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
NEWS -- Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
New video from Ian Clifford and FuelPositive:
https://themarketherald.ca/corporate-update-fuelpositive-releases-operational-costing-model-and-timeline-for-green-ammonia-production-system-2021-11-23/
The facts are that Frank owns over 20% of NIHK stock Elon Musk owns 17% of Tesla , NIHK has the first-ever EV crypto mining technology, and an EVs that will be reasonably priced for the masses.
NEWS -- Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
Vivos Inc.
Tue, November 23, 2021, 9:30 AM
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT).
Richland WA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that Johns Hopkins University VCTN, Veterinary Clinical Trials Network, is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific cancers. They have the required radioactive material license and have completed their training certification for Isopet®.
Dr. Mike Korenko stated, “Our business plan is to establish new IsoPet® regional centers across the United States and then internationally. John Hopkins University has an excellent reputation and we are excited to add Johns Hopkins as an Isopet® regional clinic. This important relationship will also help meet our objective of obtaining high quality data on a range of cancers that can be published in leading journals. These publications are the optimal way to increase awareness of Isopet® and to gain broader acceptance from the veterinarian/oncology community.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
Radiogel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The Isopet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval was required for treating skin cancer, which is the largest market sector. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet® to University animal hospitals and private veterinary clinics.
Isopet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
mailto://MKorenko@RadioGel.com
CEO stated that he will never do RS or reverse splits in any of his holdings . And our CEO has lawyers to make everything he does legally.
NEWS -- Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®
Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific cancers. They have the required radioactive material license and have completed their training certification for Isopet®.
Dr. Mike Korenko stated, “Our business plan is to establish new IsoPet® regional centers across the United States and then internationally. John Hopkins University has an excellent reputation and we are excited to add Johns Hopkins as an Isopet® regional clinic. This important relationship will also help meet our objective of obtaining high quality data on a range of cancers that can be published in leading journals. These publications are the optimal way to increase awareness of Isopet® and to gain broader acceptance from the veterinarian/oncology community.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
Radiogel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The Isopet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval was required for treating skin cancer, which is the largest market sector. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet® to University animal hospitals and private veterinary clinics.
Isopet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
mailto://MKorenko@RadioGel.com
WOW, this is the first-ever stock that I bought that the CEO owns over 20% of the shares .
A new YouTube video has been posted within the past hour.
NEWS -- Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
NEWS -- Corporate Update: FuelPositive Releases Operational Costing Model and Timeline for Green Ammonia Production System
TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is issuing the following update to share the status of the Company and its green ammonia technology. FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable clean agriculture, energy and chemical solutions to combat climate change. Its lead technology is a modular and scalable system for producing green ammonia for use across a broad spectrum of industries and applications.
“This has been an incredible year for us. In January, we became FuelPositive; in March, we signed the intellectual property acquisition deal for our green ammonia technology with Dr. Ibrahim Dincer and his team; in May, we formed our manufacturing partnership with National Compressed Air to build our prototype systems; in June we filed for our provisional patent and began to build our prototype production systems. Since then we have raised over CA$12 million, which will cover our costs to build a number of green ammonia production systems. We are on track to launch multiple “real world” demonstration pilot projects to showcase our technology throughout 2022. And – maybe the most important achievement of all – we have assembled a team of undisputed experts in their fields – from engineering and manufacturing to robotics and carbon credits,” said Ian Clifford, Chief Executive Officer and Board Chair of FuelPositive. “We are highly efficient, knowledgeable and experienced in every step we need to take along the way to commercialization. We can move much more quickly than our competitors and that is one of our great strengths!”
Critical to the commercialization of the Company’s flagship product – a modular, scalable and portable system for producing green ammonia – is a practical costing model and an aggressive timeline to be first to market. Both the costing model and the timeline will be presented in detail in a corporate update webinar being held today at 2:00 p.m. ET, providing stakeholders with an opportunity to ask questions of Chief Executive Officer Ian Clifford and Chief Operating Officer Nelson Leite.
You can register for the webinar below.
Date: Thursday, November 18, 2021
Time: 2 p.m. ET
Register: Webinar Registration (https://share.hsforms.com/1km196BPDRC6EXOU2EmZQ4A4h2fj)
Costing Model
Groups around the world are racing to make green ammonia a reality. While there are many parties working on it, attempts until now have been too expensive, putting them out of reach of end users. About 80% of traditional or “grey” ammonia, which is produced using fossil fuels, is used by the agriculture sector, primarily as fertilizer. For green ammonia to be embraced by farmers, it must be affordable. FuelPositive is targeting farming for its first demonstration pilot project.
For the purposes of this costing model, FuelPositive has worked from a case study based on a 1,800-acre farm in Manitoba, Canada, where the average price of grey ammonia in 2021 has been calculated at CA$900 per tonne. (The delivered cost of grey anhydrous ammonia to farmers in Manitoba, Canada doubled from CA$600 to over CA$1,200 per metric tonne in a period of six months this year! That averages at CA$900 per metric tonne delivered to the farm this year.)
The initial FuelPositive systems will produce up to 300 kilos (500 litres) of green anhydrous ammonia per day, which amounts to roughly 100 tonnes per year. This output is suitable for our model farm of 1,800 acres. Larger farms would simply add sufficient production capacity to meet their needs – easily done since FuelPositive’s green ammonia production units are modular, scalable and portable for precisely this purpose.
The cost of production (operating expenditure or OPEX) for the case study has been calculated by FuelPositive at approximately CA$560 per metric tonne (based on a hydrogen production efficiency rate of 65%), compared to the current average cost of CA$900 per metric tonne of grey ammonia. FuelPositive is forecasting under CA$500 per metric tonne for future systems as production efficiencies improve.
Electricity costs for the farm are estimated at CA$0.045 (4.5 cents) per kilowatt hour. This is based on the current cost of electricity paid in Manitoba, which has a carbon-free, sustainable electricity grid. The electricity cost represents the largest component of the overall cost of the green ammonia produced in the FuelPositive system.
This cost does not take into account any additional potential cost reductions related to carbon credits, which could reduce the cost by 50% or more, or the farmer’s own capacity to generate sustainable electricity for the FuelPositive system through solar or wind generation on site. Today the cost of solar power is at parity with the Manitoba grid, however the cost of renewables are predicted to continue to decline.
The key takeaways from this case study show that the FuelPositive system provides:
NEWS -- Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today released positive interim data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the first-in-man Phase 1 ReSPECT™-GBM clinical trial in patients with recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.
According to the interim data, 186RNL delivered via convection enhanced delivery (CED) is well-tolerated with favorable overall survival in adult patients at higher absorbed radiation doses (greater than 100 Gy). A positive correlation was observed between overall survival and higher absorbed radiation doses (greater than 100 Gy).
The poster, titled “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1 Trial,” outlines data from the ReSPECTTM-GBM trial, substantially funded by the U.S. National Institutes of Health/National Cancer Institute, which has thus far evaluated 22 adult patients with recurrent GBM across seven cohorts of increasing dose, treated over a six year period.
“In the ReSPECTTM trial thus far, 186RNL has been well-tolerated without dose-limiting toxicities and we believe further clinical investigation of relative efficacy is warranted,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT™-GBM clinical trial. “The open label, dose escalation trial was not designed to show efficacy but the trends observed between overall survival and key delivery parameters such as therapeutic radiation dose to the tumor are promising.”
Key findings include the following:
NEWS -- Tytan Cybernetics (“Video River Networks” OTC) announces Arrival of First Generation Tytan Electric Vehicle
TORRANCE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Tytan Cybernetics/ Video River Networks “the Company” (OTC: NIHK TWTR: @NIHKEV), a technologically innovative Electric Vehicle and Fintech company, is pleased to announce the arrival of their first generation Electric Vehicle under the Joint Venture agreement with Lingstar Co.
Completed ahead of schedule, the EVs arrived direct from the production facilities and they’re safely and securely in planning for showroom display in the near future.
“After months of hardwork and determination by Lingstar and our team, I’m pleased to share that our first Electric Vehicles have arrived in California! Our team is coming together to review and develop innovative applications for our EVs. We’re celebrating this milestone as an outlook of our commitment to the evolution of Electric Vehicle technology. Accelerating the growth of viable technologies of tomorrow is one of the main goals of Tytan Cybernetics and we look forward to the next steps ahead!” CEO Frank Igwealor.
About Tytan Cybernetics, Inc.
Tytan Cybernetics, Inc. is an Electric Vehicle and Fintech company whose focus is to develop and bring to market the next generation of high-performance state-of-the-art Electric Vehicles. The company’s current and expanding technology portfolio includes Electric Vehicles, Artificial Intelligence, Machine Learning and Robotics ("EV-AI-ML-R"), with businesses and operations in North America and Asia. With a commitment to revolutionary technology, Tytan Cybernetics is in the process of cultivating prosperous technologies to enhance consumer’s cybernetic experience.
For more information, please check the latest updates on the company's Twitter account https://twitter.com/NIHKEV
Notice Regarding Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
CONTACT:
Tytan Cybernetics/Video River Networks
370 Amapola Ave., Suite 200A
Torrance, CA 90501
mailto://contact@videorivernetworks.net
NEWS -- Drone Guarder, Inc New Chairman and CEO Issues Shareholder Letter with Upcoming Action Plan
November 16, 2021
TORRANCE, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Drone Guarder, Inc. “the company” (OTC: DRNG), @DroneGuarder, a drone technology company, combining the most technologically advanced unmanned aerial surveillance systems (UAV ‘Drone’), with revolutionary Artificial Intelligence (‘A.I’) technology, issues the following Shareholder Letter direct from Chairman and CEO, James Kennar.
Dear Shareholder,
At DNRG, our mission is to make global airspace open and accessible for companies and consumers. Drones have been continuously used in eCommerce for delivery purposes, construction for monitoring hazardous areas, agriculture for planting and maintaining crops, and the military. We will transform how businesses collect and manage drone data. DNRG is broadening its focus over time through a series of mergers and acquisitions through creating a platform that stretches beyond the military and agricultural space to a more end-to-end solution, with drones, and especially software and AI across several different applications. DNRG’s user-friendly platform makes it possible for companies of any size to improve their workflows through scalable image processing, data storage, and real-time sharable drone maps and 3D models. We're unifying the commercial drone industry under one roof by providing the platform to connect software developers, and hardware partners, with powerful tools to integrate aerial data into day-to-day operations.
For example, the agriculture drone market is predicted to be worth US$32.4 billion – an indication that the industry is beginning to recognize the benefits over more traditional methods, such as ground mapping. According to a report published by the Intergovernmental Panel on Climate Change (IPCC) the use of drones in the agriculture industry is steadily growing as part of an effective approach to sustainable agricultural management that allows agronomists, agricultural engineers, and farmers to help streamline their operations, using robust data analytics to gain effective insights into their crops. Crop monitoring, for example, is made easier by using drone data to accurately plan and make ongoing improvements, such as the use of ditches and evolving fertilizer applications. Products can be accurately traced from farm to fork using GPS locations for every point in the journey, rather than more traditional time and labor-intensive.
In continuing with our predecessor’s vision, former CEO, Frank I Igwealor, I’m excited to share DNRG’s Action Plan for the upcoming months:
NEWS -- NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed yesterday, on November 15, 2021. The submission can be downloaded from the SEC website at: https://www.sec.gov/Archives/edgar/data/1379006/000110465921139231/nnvc-20210930x10q.htm .
The Company reported that it had approximately $19.89 million of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $0.87 million, as of September 30, 2021. The Company has no debt, and Stockholder's equity was approximately $28.30 million. During the three-month period ended September 30, 2021 approximately $0.72 million in cash was used toward operating activities. The Company had no revenues. (All figures are unaudited).
The Company believes it has sufficient funds for initial human clinical trials of at least one of its drug candidates.
The Company is currently focused on advancing our drug candidates for treatment of patients with SARS-CoV-2 infection towards human clinical trials, in response to the continuing global COVID-19 pandemic. Of these, NV-CoV-2 is designed to act by a novel mechanism of action, that we call "Re-infection Blocker". The Company is working on regulatory submission documents for NV-CoV-2 at present.
NV-CoV-2 was found to be a broad-spectrum, pan-coronavirus drug candidate in pre-clinical studies. Escape of virus due to variants is expected to be highly unlikely because of this broad-spectrum antiviral activity of NV-CoV-2.
NV-CoV-2 has been found to be extremely safe and non-mutagenic in GLP and Non-GLP Safety/Toxicology studies.
The Company has developed "oral gummies" formulation of NV-CoV-2 successfully. Oral gummies are expected to be more acceptable to children and older patients because of slow dissolution in the mouth and palatability than oral pills that may be difficult to swallow. NV-CoV-2 has demonstrated good oral bioavailability in animal studies. The Company believes that an effective oral drug to treat COVID-19 remains an unmet medical need.
The Company has also developed NV-CoV-2 formulations for injection, infusion and direct lung inhalation using a simple mouthpiece. The inhalation drug formulation is expected to benefit severely ill patients as it enables delivering much higher levels of drug (than infusion or oral dosing) directly to the lung tissue thereby helping to minimize the lung viral load and lung damage, for rapid recovery of hospitalized patients.
In addition to NV-CoV-2, the Company is also developing another anti-coronavirus drug candidate, NV-CoV-2-R. This drug candidate is comprised of holding remdesivir inside our polymeric drug candidate NV-CoV-2 by a process known as encapsulation. Thus NV-CoV-2-R is potentially capable of (1) direct attack on extracellular virus, to break the "re-infection cycle" by virtue of NV-CoV-2, and (2) attack on intracellular reproduction of the virus to break the "replication cycle" as has been validated for remdesivir. If both of these cycles are broken, in theory, it is expected to result in a cure of the virus infection.
NanoViricides is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility. The Company intends to produce its drugs for clinical trials in this facility. The Company has the capability to produce sufficient drugs for about 1,000-5,000 patients in a single batch of production, depending upon the drug and the dosage. This production capacity is anticipated to be sufficient for first-in-human use in the current SARS-CoV-2 pandemic for our anti-coronavirus drug in development, as well as for the anticipated clinical trials of NV-HHV-101 skin cream for the treatment of shingles.
The Company has previously completed IND-enabling studies for its drug candidate NV-HHV-101 for the treatment of shingles rash caused by reactivation of the chickenpox virus (aka varicella-zoster virus, VZV). The Company plans on further developing the shingles drug candidate into human clinical trials after clinical trials of our COVID-19 drug candidate. The Company has additional drugs in its pipeline at various pre-clinical stages that it plans to develop towards regulatory approvals after the COVID-19 and Shingles drug clinical trials.
About NanoViricides
NanoViricides, Inc. (the "Company")(https://www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.
The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with remdesivir encapsulated in it. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines.
Contact:
NanoViricides, Inc.
mailto://info@nanoviricides.com
Public Relations Contact:
MJ Clyburn
TraDigital IR
mailto://clyburn@tradigitalir.com
SOURCE: NanoViricides, Inc.
View source version on accesswire.com:
https://www.accesswire.com/673062/NanoViricides-Has-Filed-Quarterly-Report-for-Period-Ending-September-30-2021--Has-Sufficient-Cash-Coronavirus-Drug-Candidate-Moving-Towards-Clinical-Trials
NEWS -- Nanomix Completes Changes to Corporate Name and Ticker Symbol
NEWS -- OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
CARLSBAD, Calif., November 15, 2021--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from a Phase 1/2a clinical study of its lead product candidate, OpRegen®, an investigational retinal pigment epithelium ("RPE") cell transplant therapy currently in development for the treatment of dry age-related macular degeneration ("AMD"), were presented at the 2021 American Academy of Ophthalmology (AAO) 125th Annual Meeting. The presentation, "OpRegen Trial: Phase 1/2a Dose Escalation Study of Human Embryonic Stem-Cell Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced AMD, (Geographic Atrophy) (NCT02286089): Interim Results and Further Insights from Imaging Analyses" was presented on November 13, 2021 as part of the Gene and Cell-Based Therapies Session, by Michael S. Ip, M.D., Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles. These updated results include a minimum of 12 months of follow-up in all 12 patients treated in Cohort 4, which as a group had better baseline vision and smaller areas of geographic atrophy ("GA") at baseline than earlier cohorts. Overall, in the study (N=24), OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events not previously reported.
Dr. Ip stated, "I am excited about several aspects of the optical coherence tomography, or OCT, observations following our team’s detailed image review. First, there appear to be resolution of incomplete RPE and outer retinal atrophy or iRORA in several patients. Additionally, there is evidence of resolution of areas with features of cRORA, or complete loss of the RPE and outer retinal tissue, in some eyes, which has not been previously reported. Finally, there are statistically significant improvement, or trends toward improvement, in the treated eyes versus the fellow eyes as compared from baseline to month 12 post-treatment in critical retinal tissue. I look forward to our group completing these analyses in the remaining patients as data become available."
"We are encouraged by this additional supporting evidence obtained from independent analyses of the OpRegen data in patients with atrophic AMD," added Brian M. Culley, Lineage CEO. "When OpRegen is implanted in the transitional zones of the GA in patients with less advanced disease, reversing damage, or even simply arresting further progression for several years, has been shown to be possible. Restoration of retinal tissue is a compelling finding compared to conventional approaches which to date have only shown an unexceptional slowing of progression. In addition to being well tolerated to date, the durability of changes to areas of atrophy and improvements in visual acuity observed point to the urgency to further evaluate OpRegen in a larger, controlled trial. We currently are preparing for multiple engagements with FDA to discuss aspects of OpRegen’s designation, our manufacturing plans, and the design of a later-stage clinical trial. We expect the first of these engagements will begin in the fourth quarter of 2021 and continue in the first quarter of 2022."
OpRegen Phase 1/2a Interim Clinical Results
NEWS -- NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. Additionally, the Company has developed formulations for direct inhalation into lungs to benefit severely ill hospitalized patients. The Company also reports strong safety of NV-CoV-2 on several parameters in animal models.
NV-CoV-2 has been found to be an Extremely Safe and Non-mutagenic Drug, as described below:
The Company reports that NV-CoV-2 has been found to be non-immunogenic and non-allergenic. Further, it has not caused any hypersensitivity or adverse reactions at injection site or other adverse events in multiple animal studies. It was safe and well tolerated at very high dosages in single and multiple-dosing studies below the maximum tolerable dose (MTD) in animal models, based on available data. The maximum tolerable dosage in rats was determined to be 1,500 mg/Kg.
The Company also reports that NV-CoV-2 has been found to be non-mutagenic in a standard GLP Ames Test.
The Company believes that the extremely strong safety observed in animal models should be indicative of a strong safety signal anticipated in Phase 1 human clinical trials.
The non-immunogenicity, non-allergenicity, and lack of hypersensitivity or adverse reactions at injection site seen in animal models with single and repeated injections leads the Company to postulate that it may be possible to give a therapeutic dose of NV-CoV-2 in humans via a simple slow-push injection rather than an infusion. If this proves out in clinical trials, it would enable treating moderate cases without hospitalizing the patients. This is an important unmet need that would help significantly reduce the severe and intense load on hospitals and health-care workers that occurs during the waves of the global COVID-19 pandemic.
NV-CoV-2 and NV-CoV-2-R Drug Formulations for Oral, Injectable, Infusion, and Direct Lung Inhalation:
NanoViricides has developed formulations of both NV-CoV-2 and NV-CoV-2-R to meet the needs of different levels of disease severity and different types of patients.
The Company has recently completed the development of an oral gummies ("chewable gel") formulation of NV-CoV-2. The Company believes that this formulation may have advantages in terms of drug bioavailability over oral pills, because of partial sublingual absorption that avoids the gastrointestinal tract. NanoViricides maintains that this oral gummies formulation would be very attractive to patients, especially children, over oral pills. This formulation would be for the benefit of symptomatic non-hospitalized patients, Additionally, the simplicity of administration is expected to enable its prophylactic use as well.
The Company has previously developed an injectable formulation of NV-CoV-2 that it believes may not require infusion, allowing treatment of severe cases without hospitalization. This is an important unmet need for reducing strain on hospital systems during waves of the global COVID-19 pandemic.
Previously, the Company has developed formulations for infusion for both NV-CoV-2 and NV-CoV-2-R, to treat severely ill hospitalized patients.
NanoViricides has also very recently developed formulations of both NV-CoV-2 and NV-CoV-2-R for direct inhalation into lungs using a simple nebulizer. This inhalation formulation is developed to benefit very severely ill patients with significant lung pathology. Direct inhalation of the drug would result in highest possible levels of the drug to be achieved in lungs thereby maximizing antiviral effect, and minimizing lung viral load. This is expected to help minimize lung damage, enabling the patient to recover rapidly.
The Company has previously demonstrated that NV-CoV-2 was highly effective in multiple cell culture studies against unrelated coronaviruses including SARS-CoV-2 (S-protein pseudovirion), h-CoV-NL63 (NL63), and h-CoV-229E (229E). 229E causes common colds. NL63 causes a COVID-19-like lung pathology in humans, but the disease is not very severe. SARS-CoV-2 has caused the current global pandemic that continues with multiple waves driven by evolution of new variants. Thus the Company has established the broad-spectrum pan-coronavirus activity of NV-CoV-2.
As new variants emerge, the effectiveness of vaccines has continued to drop, the protection from the antibodies developed in response to the vaccine has continued to decrease, and antibody drugs have become progressively less effective. Thus a broad-spectrum pan-coronavirus drug is needed to help end the pandemic. NanoViricides has recognized this need right at the onset and believes it has successfully developed drug candidates that precisely satisfy this as-yet unmet need.
NanoViricides asserts that there is a much lower probability of generation of escape mutants against NV-CoV-2 (as compared to the classical types of drugs) (1) because it is designed to create a multi-point attack on the virus thereby completely disrupting the virus structure, and (2) because of the observed broad-spectrum activity of NV-CoV-2 against multiple types of distinctly different coronaviruses including SARS-CoV-2.
"We believe that NV-CoV-2 and NV-CoV-2-R would be highly effective drugs against SARS-CoV-2, based on multiple animal studies data," commented Dr. Anil Diwan, Chairman and President of the Company, adding, "We believe that NV-CoV-2 may help end the pandemic if it is shown to be effective in human clinical trials."
About NanoViricides
NanoViricides, Inc. (the "Company") (http://www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. We are developing clinical candidates for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Our other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the Company has several antiviral programs in various pre-clinical stages.
The Company is now working on tasks for completing an IND application for its COVID-19 drug candidates. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with remdesivir encapsulated in it. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: human Coronavirus infections, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines.
Contact:
NanoViricides, Inc.
mailto://info@nanoviricides.com
http://www.nanoviricides.com
Public Relations Contact:
MJ Clyburn
TraDigital IR
mailto://clyburn@tradigitalir.com
SOURCE: NanoViricides, Inc.
View source version on accesswire.com:
https://www.accesswire.com/672810/NanoViricides-Completes-Oral-Gummies-and-Lung-Inhalation-Formulations-Development-for-its-Non-Mutagenic-Safe-Broad-Spectrum-COVID-19-Clinical-Drug-Candidate-NV-CoV-2
Catalytic converters are already developed .
NEWS -- Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that on November 11, 2021, it granted option awards to Norman LaFrance, M.D. Consistent with the disclosures contained in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on September 13, 2021, the Company agreed to grant these equity awards on Dr. LaFrance’s start date to induce Dr. LaFrance to commence employment as its Chief Medical Officer.
The approved option awards are options to purchase up to 120,000 shares of the common stock of the Company. The options are scheduled to vest over four years, with one-fourth of the options vesting on the first anniversary of the grant date with the remaining options vesting thereafter in equal monthly installments. The vesting of the options is also subject to certain requirements, including Dr. LaFrance’s continued service as an employee of the Company through the applicable vesting dates. The exercise price of the options is equal to the closing price of the Company’s common stock on November 11, 2021, the grant date.
The Company believes that these equity grants create a strong alignment of interests between Dr. LaFrance and Company shareholders. The equity awards were granted outside of the Company’s 2020 Incentive Plan but generally have terms and conditions consistent with those set forth in that plan. The Company has filed a Form S-8 covering these equity awards.
About Norman LaFrance
Prior to joining the Company, Dr. LaFrance served as the Chief Medical Officer, Senior Vice President, at Jubilant Pharma Ltd, where he was responsible for all Pharma Medical and Regulatory Affairs activities. Dr. LaFrance also served as Global Chief Medical Officer at IBA Molecular from 2010 to 2012, and as Senior Vice President, Clinical Development and Chief Medical Officer at Molecular Insight Pharmaceuticals from 2007 to 2010. Prior to joining Molecular Insight Pharmaceuticals, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership.
Dr. LaFrance received his bachelor of science and master of engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his medical degree from the University of Arizona, College of Medicine, Tucson.
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, MA / ACCESSWIRE / November 11, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported topline results from the Company's Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19. Brilacidin is being developed for treatment of COVID-19 under FDA Fast Track designation.
Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study's primary endpoint based on clinical status. Clinical status endpoints contain a degree of subjectivity that may impact outcomes of COVID-19 trials. Additional analysis of topline and all study endpoints is ongoing.
"Though disappointed with these topline results, treating moderate-to-severe COVID-19 is an exceptionally difficult patient population," said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "Companies, such as Merck and Regeneron, also did not show clinical benefit in these groups of patients, although both went on to refocus their development efforts in mild-to-moderate COVID-19 and achieve success. Regarding our Brilacidin antiviral program in general, collaborations with NIH scientists and academic researchers to explore Brilacidin's broad-spectrum antiviral activity in different viruses are ongoing. Initial feasibility work to formulate Brilacidin for potential prophylactic use via inhaled delivery, to leverage Brilacidin's unique virucidal and blocking antiviral properties, also is underway. There are many paths to pursue in the antiviral space. We believe Brilacidin holds tremendous promise as a differentiated antiviral drug candidate and plan to continue its development in this area of great opportunity and unmet need."
Topline safety data showed Brilacidin was generally well-tolerated, with frequency of treatment-emergent adverse events similar between study arms. The number of patients who died totaled eight, four each between active and placebo. The overall mortality rate (6.67%) in the trial was approximately one-half of what is typically observed in this patient population.
The randomized, double-blind, placebo-controlled trial (see https://clinicaltrials.gov/ct2/show/NCT04784897) evaluated the efficacy and safety of intravenous Brilacidin administered for 3 or 5 days in addition to standard of care. In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug. Patients were evenly split between male and female, with a majority categorized as experiencing severe COVID-19 at baseline. Most patients were under 65 years old, with an average age of 58.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its potential impact on SARS-CoV-2 (COVID-19) and other viruses. Other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the United States and other jurisdictions, including without limitation that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company's ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACTS:
Innovation Pharmaceuticals Inc.
Leo Ehrlich
mailto://info@ipharminc.com
SOURCE: Innovation Pharmaceuticals
View source version on accesswire.com:
https://www.accesswire.com/672330/Innovation-Pharmaceuticals-Announces-Topline-Results-from-Phase-2-Clinical-Trial-of-Brilacidin-for-COVID-19
From this Conference call Nov 4 https://share.hsforms.com/1iQ2gaMXcQpeCUpizBWfpqg4h2fj
NEWS -- FuelPositive Corp. to Host Live Corporate Update Webinar on November 18, 2021 at 2 p.m. ET
TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is pleased to announce that the Company’s Chief Executive Officer Ian Clifford, and Chief Operating Officer Nelson Leite, will be delivering a corporate update on current operations and upcoming milestones, including the costing model for its flagship product: a modular, scalable production system for green ammonia.
You can register for the webinar below.
Date: Thursday, November 18, 2021
Time: 2 p.m. ET
Register: https://share.hsforms.com/1km196BPDRC6EXOU2EmZQ4A4h2fj
“We have made considerable progress since our last corporate update in September, with the fabrication and assembly of our prototype production systems well under way now. This significant move, from the research phase to the development and build-out of full-sized systems, has allowed us to work out costing and timing details that are critical to the commercialization of our products,” said Ian Clifford, CEO of FuelPositive. “We have received a great deal of interest in recent weeks. This webinar will provide an opportunity for our stakeholders to get their questions answered.”
FuelPositive COO Nelson Leite will join the webinar to present a more detailed look at the costs associated with the Company’s green ammonia production system, as well as the time frame it expects to follow leading up to commercialization. “We are at a point now where the forecasts we are making should be reliable. We recognize there could be some delays due to worldwide supply chain problems. If we have any significant delays in critical deliveries, we will let everyone know and share our updated schedule. We are building the commercial prototypes, it is going well, and we are enthusiastic about getting our systems into the field throughout 2022,” said Leite.
Have Questions?
Management will be available to answer your questions following the presentation on the webinar platform. You may submit your question(s) beforehand in the registration form or by email: mailto://FuelPositive@rbmilestone.com.
About FuelPositive
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.
By focusing on technologies that are clean, economically advantageous/realizable and that leverage existing infrastructure, the Company aims to change the course of climate change through practical solutions that can be implemented now.
The Company’s core technology, a modular and scalable carbon-free NH3 system, takes air, water and sustainable electricity and synthesizes it into a non-polluting chemical for multiple applications, including fertilizer for farming, fuel for internal combustion engines and a solution for grid storage. It is being considered as a replacement for fossil fuels and as a key enabler of the hydrogen economy.
The company’s most recent corporate update, presented in September, can be found here (https://share.hsforms.com/1iQ2gaMXcQpeCUpizBWfpqg4h2fj).
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company, including the expected expenditures of the proceeds of the private placement, are forward-looking statements. These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Mr. Ian Clifford
Chief Executive Officer
mailto://mailbox1@fuelpositive.com
Investor Relations (United States)
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
NEWS -- Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), a rare complication in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord, affecting nearly 5% of people living with cancer. The Company recently announced clearance of its Investigational New Drug (IND) application from the FDA, and expects to initiate patient accrual in the ReSPECT-LM Phase 1 dose escalation clinical trial of 186RNL in the fourth quarter of 2021.
“The incidence of LM is rising and represents a rapidly progressing and fatal complication of several cancer types,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “Based on our clinical experience with 186RNL in glioma and preclinical studies in LM models, we are optimistic that 186RNL may have a therapeutic role in management of this increasingly common cancer.”
Fast Track designation confers several benefits to the drug development program including 1) more frequent meetings with FDA to discuss the drug's development plan, 2) more frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers, 3) eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and 4) Rolling Review, which means that a drug company can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
About the ReSPECT-LM Study
The ReSPECT-LM clinical trial is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1 study. It will evaluate the maximum tolerated dose, maximum feasible dose, safety, and efficacy of a single administration of 186RNL via intraventricular catheter for LM following standard surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events/serious adverse events and dose limiting toxicities. Secondary endpoints include overall response rate, duration or response, progression free survival, and overall survival.
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. LM occurs in approximately 5% of people with cancer, or 110,000 people in the U.S. each year, and is usually terminal with a median survival of approximately 2-3 months following treatment. LM occurs with cancers that are most likely to spread to the central nervous system. The most common cancers to include the leptomeninges are breast cancer, lung cancer, and melanomas.
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “plan,” “can,” “design,” “intend,” “potential,” “expect,” “target,” “focus,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the Company’s anticipated expenditures, including research and development, sales and marketing, and general and administrative expenses; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; the Company’s ability to expand clinical testing of 186RNL to additional sites and additional indications, such as leptomeningeal metastases and pediatric brain cancer; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; the potential size of the market for the Company’s product candidates; the Company’s research and development efforts; the Company’s IP strategy; competition; future development and/or expansion of its product candidates and therapies in its markets; its ability to obtain and maintain regulatory approvals including statements regarding the Company’s intent to submit any new IND application; expectations as to the Company’s future performance; the Company’s need for additional financing and the availability thereof; its ability to fully access its equity line with Lincoln Park; any changes to its interest expenses; the Company’s ability to continue as a going concern; operating results; and the potential enhancement of the Company’s cash position through development, marketing, and licensing arrangements.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
TYCY is my guess!
We have to ask ourselves, Would Ian be making statements like, 'under promise, and over deliver' if something wasn't going to happen sooner than later. I think very interesting times are coming.
NEWS -- Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update
Conference Call to be Held on Wednesday, November 10, 2021 at 5:00 p.m. (EST)
DUBLIN, Ohio, November 03, 2021--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, November 10, 2021 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2021.
Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress.
Questions will not be taken during the conference call, however you may submit questions up to 24 hours in advance of the meeting by sending an email to info@navidea.com. We ask that you limit your questions to those that are relevant to our business. Questions may not be addressed if they are, among other things, profane, irrelevant to our business, related to pending or threatened litigation, disorderly, or repetitious of statements already made. In addition, questions may be grouped by topic by our management with a representative question read aloud and answered. Questions will be addressed in the Q&A portion of the conference call, and we may also respond to questions on an individual basis or by posting answers on our website after the call.
To participate in the call and webcast, please refer to the information below:
Event: Third Quarter 2021 Earnings Conference Call and Business Update
Date: Wednesday, November 10, 2021
Time: 5:00 p.m. (EST)
U.S. & Canada Dial-In: 877-407-0312
International Dial-In: +1 201-389-0899
Conference ID: 13724382
Webcast Link: https://webcast-eqs.com/navidbioph20211110/en
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006154/en/
Contacts
Navidea Biopharmaceuticals, Inc.
Jeff Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
NEWS -- Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
CARLSBAD, Calif., November 03, 2021--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2021 financial and operating results on Wednesday, November 10, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Wednesday, November 10, 2021, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2021 financial and operating results and to provide a business update.
Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage’s website (https://investor.lineagecell.com/events-and-presentations/upcoming-events). A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through November 18, 2021, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 9352189.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005019/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Mike Biega
(mailto://Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
NEWS -- Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT™-GBM Trial
Company Management and Principal Investigators to Discuss Trial Data
Webinar Scheduled for Thursday, November 18, 2021 at 4:00 - 5:00 p.m. ET
AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will host a key opinion leader roundtable discussion on the ReSPECT-GBM trial on Thursday, November 18, 2021, 4:00 to 5:00 p.m. ET.
The webinar will feature a comprehensive discussion about the ongoing ReSPECT-GBM trial including key safety, tolerability, dosing, feasibility and efficacy data. Speakers will include:
FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Defining the Ongoing Disruption Within the Energy, Transportation and Food Sectors
November 2, 2021 at 12:42pm
NEWS -- Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® in Stage III Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
KNOXVILLE, TN, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that results from a meta-analysis of response, survival, and safety data from the Company’s Phase 2 and 3 clinical trials (NCT00521053 and NCT02288897, respectively) and expanded access program (EAP) (NCT01260779) of single-agent cancer immunotherapy PV-10 (rose bengal disodium) for the treatment of Stage III cutaneous melanoma was presented at the SMR 2021 Virtual Congress (the Society for Melanoma Research annual meeting), which was held online from October 28th to 31st.
A copy of the poster presentation is available on Provectus’ website at https://www.provectusbio.com/media/docs/publications/SMR-2021-PV-10-in-Stage-III-Melanoma.21Oct2021.pdf.
Highlights of the SMR 2021 presentation:
InvestorNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Inching Closer to a World with Sustainable, Clean Fossil Fuel Replacement
FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has achieved several milestones and made strategic investments that bring it even closer to its ultimate goal of providing sustainable, clean energy to reduce carbon emissions. The company, which is pushing for the change from fossil fuels, has appointed André Mech, who will lend his years of experience to the strategic carbon credit and emissions reduction specialist position, helping FuelPositive sell its carbon credits in the same way Tesla does. With the hydrogen economy being at the core of the company’s agenda, FuelPositive is spearheading the modular and scalable carbon-free ammonia industry. “To date, FuelPositive has managed to achieve three main milestones for the 2021 fiscal year: process determination, primary component vendor selection and procurement, and engineering design,” reads a recent article. “Going forward into 2022, the company plans to put systems in place for demonstration projects with partners and ramp up production capability in the early half of the year and start shipping commercial systems in the last quarter of 2022.”
To view the full article, visit https://ibn.fm/B2PRr
About FuelPositive Corporation
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean energy solutions, including carbon-free ammonia (“NH3”), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/realizable and that leverage existing infrastructure, the company aims to change the course of climate change through practical solutions that can be implemented now. The company’s core technology, carbon-free NH3, takes air, water and sustainable electricity and converts it to a non-polluting chemical for multiple applications, fertilizer for farming, fuel for internal combustion engines and a solution for grid storage. It is being considered as a replacement for fossil fuels and as a key enabler of the hydrogen economy. For more information, visit www.FuelPositive.com.
NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
https://www.InvestorWire.com
mailto://Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Whales are back!
NEWS -- Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Treatment of Checkpoint-Refractory Advanced Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
Canadian Jenn twitter Account has been suspended!
NEWS -- Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Data demonstrated Rhenium-186 NanoLiposome (186RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure
The analysis of 3D drug distribution and tumor response shows image monitoring is a predictive tool to evaluate delivery and treatment effectiveness
Compared to sealed source brachytherapy, 186RNL offers minimally invasive, convenient delivery
AUSTIN, Texas, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting indicating Rhenium-186 NanoLiposome (186RNL) delivered to patients with recurrent glioblastoma (GBM) through convection enhanced delivery results in predictable distribution and stable retention to the targeted tissues, providing days of sustained, localized radiation treatment to the tumor.
Data from the ePoster titled “Image-guided Rhenium-186 NanoLiposome (186RNL) brachytherapy in the treatment of recurrent glioblastoma: technique, image analysis, dosimetry, and monitoring” demonstrated the following: